Evidence map›Paper›PMID 39137945›Full record

ArticleGenes & development2024

Hyd/UBR5 defines a tumor suppressor pathway that links Polycomb repressive complex to regulated protein degradation in tissue growth control and tumorigenesis.

Pei Wen, Huiyan Lei, Hua Deng, Su Deng, Carla Rodriguez Tirado, Meiling Wang, Ping Mu, Yonggang Zheng, Duojia Pan

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Genes & development, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.

0numbers the graph read from it
0cells of the map it votes in
5citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

5 citing papers in PubMed.

  1. Review
  2. Switching of the c-Myc protein degradation pathway depending on the PP2A-B55α complex levels.Proceedings of the National Academy of Sciences of the United States of America · 2026
    Article
  3. Article
  4. Article
  5. Epigenetic Regulation in Drosophila Tumor Models.Advances in experimental medicine and biology · 2025
    Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors.

Pei Wen *Department of Physiology, Howard Hughes Medical Institute, University of Texas Southwestern Medical Center, Dallas, Texas 75390, USA.
Huiyan Lei *Department of Physiology, Howard Hughes Medical Institute, University of Texas Southwestern Medical Center, Dallas, Texas 75390, USA.
Hua Deng *Department of Physiology, Howard Hughes Medical Institute, University of Texas Southwestern Medical Center, Dallas, Texas 75390, USA.
Su DengDepartment of Molecular Biology, Harold C. Simmons Comprehensive Cancer Center, University of Texas Southwestern Medical Center, Dallas, Texas 75390, USA.
Carla Rodriguez TiradoDepartment of Molecular Biology, Harold C. Simmons Comprehensive Cancer Center, University of Texas Southwestern Medical Center, Dallas, Texas 75390, USA.
Meiling WangDepartment of Physiology, Howard Hughes Medical Institute, University of Texas Southwestern Medical Center, Dallas, Texas 75390, USA.
Ping MuDepartment of Molecular Biology, Harold C. Simmons Comprehensive Cancer Center, University of Texas Southwestern Medical Center, Dallas, Texas 75390, USA.ORCID 0000-0003-0955-0896
Yonggang ZhengDepartment of Physiology, Howard Hughes Medical Institute, University of Texas Southwestern Medical Center, Dallas, Texas 75390, USA.ORCID 0000-0002-3326-4614
Duojia PanDepartment of Physiology, Howard Hughes Medical Institute, University of Texas Southwestern Medical Center, Dallas, Texas 75390, USA; duojia.pan@utsouthwestern.edu.ORCID 0000-0003-2890-4645

Funding

Resource Component: Acquisition, maintenance and distribution of Drosophila stocksP40OD018537 · OD · TRUSTEES OF INDIANA UNIVERSITY · PI Annette L. Parks · 2014 to 2026
$13.5M
DROSOPHILA GENOMICS RESOURCE CENTERP40OD010949 · OD · TRUSTEES OF INDIANA UNIVERSITY · PI Andrew Zelhof · 2012 to 2026
$9.4M
Control of Cell Number in Developing RetinaR01EY015708 · NEI · UT SOUTHWESTERN MEDICAL CENTER · PI DUOJIA PAN · 2004 to 2026
$8.8M
Elucidating the Molecular Role of SYNCRIP in Prostate Cancer and AR Targeted Therapy ResistanceR37CA258730 · NCI · YALE UNIVERSITY · PI Ping Mu · 2021 to 2026
$2.7M
Unveiling the Role of UBE2J1 as the E2 Ubiquitin Conjugating Enzyme in Androgen Receptor DegradationR01CA292949 · NCI · YALE UNIVERSITY · PI Ping Mu · 2024 to 2026
$2.1M
Overcome the lineage plasticity conferred targeted therapy resistance in advanced prostate cancerR00CA218885 · NCI · UT SOUTHWESTERN MEDICAL CENTER · PI MU, PING · 2018 to 2020
$719k
Dissecting the role of UBE2J1 in prostate cancerF31CA261019 · NCI · UT SOUTHWESTERN MEDICAL CENTER · PI RODRIGUEZ-TIRADO, CARLA SOFIA · 2022 to 2023
$57k
NCI NIH HHS F31 CA261019NCI NIH HHS R00 CA218885NCI NIH HHS R01 CA292949NCI NIH HHS R37 CA258730NEI NIH HHS R01 EY015708NIH HHS P40 OD010949NIH HHS P40 OD018537
6 · The paper itself

Abstract

Tumor suppressor genes play critical roles in normal tissue homeostasis, and their dysregulation underlies human diseases including cancer. Besides human genetics, model organisms such as

Indexed as

CarcinogenesisDrosophila ProteinsProteolysisUbiquitin-Protein LigasesAnimalsDrosophila melanogasterGenes, Tumor SuppressorHumansPolycomb-Group ProteinsPolycomb Repressive Complex 1Tumor Suppressor ProteinsUbiquitinationDrosophila Proteinshyd protein, DrosophilaPolycomb-Group ProteinsPolycomb Repressive Complex 1Tumor Suppressor ProteinsUbiquitin-Protein LigasesBowlE3 ubiquitin ligasehyperplastic discLinesLINS1OSR1/2Polycomb repressive complexprostate cancertumor suppressorUBR5

Identifiers

PMID39137945
PMCPMC11368183

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.